News for Expanded Access Protocols

StemSynergy Therapetics Inc is now accepting applications for Expanded Access Protocols (EAPs) as part of an upcoming clinical trial for patients with Wnt- and Notch-dependent cancers including but not limited to esophageal adenocarciomas, colorectal cancers, triple negative breast cancers, lung cancers, and sarcomas. This program is designed to provide eligible patients with early access to first-in-class, innovative investigational treatments under expert medical supervision.

“We are excited to extend our protocol to accommodate more participants, who can benefit from and contribute to these cutting-edge investigational treatments” said Dr. Capobianco, President of StemSynergy Therapetics Inc.

To learn more about eligibility and the application process, contact us at info@stemsynergy.com

About StemSynergy

StemSynergy Therapeutics is a pharmaceutical company focused on the discovery and development of novel small-molecule drugs that target signaling pathways fundamental to cancer. Our mission is to optimize efficacy against the pathways required to drive cancer stem cells, such as the Wnt, Notch, and Myc signaling pathways.

Contacts
Anthony Capobianco, Ph.D., President
info@stemsynergy.com